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CLINICAL HISTORY
An 8-year-old boy with no significant past medical history pre-
sented to the emergency department following 2 weeks of progres-
sive headaches, fatigue, and vomiting. On physical examination,
the patient had no fever, or focal motor or sensory neurological
deficits. Initially diagnosed with an H1N1 viral upper respiratory
and gastrointestinal infection, he was discharged home with con-
servative management. After failure to improve over the next
several days, a superimposed bacterial infection was suspected. He
was given a course of oral antibiotics, which failed to improve his
symptoms. Imaging revealed a large, heterogenously enhancing
mass measuring 5.6 × 4.7 × 5.2 cm, which contained partially
hemorrhagic material centered within the left thalamus extending
into the body of the lateral ventricle (Figures 1a). Gross total
resection of the tumor was confirmed by postoperative imaging.
Staging revealed no metastases. The patient was discharged home
1 week later.
NEUROPATHOLOGICAL FINDINGS
Grossly, the tumor submitted consisted of multiple pieces of
friable, tan tissue fragments altogether measuring 2 × 2 × 0.5 cm.
Microscopically, the tumor was formed by pleomorphic, fre-
quently multinucleated bizarre cells with numerous mitotic figures
and multiple abnormal spindles (Figure 1b), multifocal tumor
necrosis, calcifications, and exuberant microvascular proliferation
(Figure 1c). Immunostaining of the sections showed many areas of
neoplasm staining positively for synaptophysin (Figure 1d), and
occasional cells positive for glial fibrillary acidic protein (GFAP)
(Figure 1e) and vimentin. Positive Tuj1 staining was seen in some
of these areas as well. Few cells were positive for S-100 protein,
and none for NeuN or neurofilament protein. However, p53 as well
as epidermal growth factor receptor (EGFR) (Figure 1f) showed
robust multifocal staining. MIB-1 proliferation index was high,
approaching close to 100% in some areas.
What is your diagnosis?
A B C
FED
Figure 1.
doi:10.1111/bpa.12074
601Brain Pathology 23 (2013) 601–602
© 2013 International Society of Neuropathology
DIAGNOSIS
WHO Grade IV glioblastoma multiforme (GBM) with extensive
neuronal differentiation.
DISCUSSION
GBM is the most common primary brain tumor occurring in the
United States, accounting for an estimated 13,000 deaths each year
(5). GBM is morphologically heterogenous with the histological
hallmarks of extensive microvascular proliferation, prominent
necrosis, and frequent mitoses. As an astrocytic neoplasm, GBM
typically stains positively for GFAP and S-100 protein. In addition
to the classic form of glioblastoma, 2 histological variants and
several other patterns have been defined including gliosarcoma,
giant cell GBM, glioblastoma with lipidized cells, small cell gliob-
lastoma, glioblastoma with oligodendroglioma component, and
glioblastoma with heterologous differentiation (1).
Gangliogliomas are typically well-differentiated neoplasms
containing both neuronal and glial components. Though rare,
several reports have described the malignant transformation of
well-differentiated gangliogliomas into a GBM, with tumor
microscopy revealing extensive astrocytic proliferation, high
mitotic activity, endothelial proliferation, and cellular pleomor-
phism with multinucleated cells (2, 4). Both p53 mutations and
inactivation of p16 have been implicated in the malignant trans-
formation of gangliogliomas (2, 4).
No published reports have described a primary brain neoplasm
exhibiting features of both glioblastoma as well as multiple regions
of extensive neuronal differentiation. The documented experiences
have been limited to case reports involving children and adoles-
cents with malignant conversion of a known, well-differentiated
ganglioglioma into GBM, as well as small case series of malignant
glioneural tumors (2, 3). The diagnosis of malignant glioneural
tumors is dependent on antibody positivity for neurofilament
protein, NeuN, synaptophysin, and chromogranin, in addition to
frequent mitoses (6). Such tumors pose unique questions regarding
their biology and whether the two components reflect a “collision”
between two separate neoplastic processes, or if the neuronal com-
ponent arose from pluripotent precursor cells within the tumor.
In our patient, there was no indication of malignant conversion
from ganglioglioma, and negative immunostaining for neuro-
filament protein and NeuN is inconsistent with the diagnosis of
malignant glioneural tumor. The numerous areas of positive stain-
ing for synaptophysin or Tuj1 suggested extensive neuronal differ-
entiation within the GBM.As such, following gross total resection,
the patient was started on temozolomide followed by focal irra-
diation and erlotinib. He survived 257 days (8 months, 15 days)
after diagnosis.
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